Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.45 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | DRD3 | P35462 | 3/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.44 |
| ▸ | HRH2 | P25021 | 3/20 | 0.44 |
| ▸ | HRH1 | P35367 | 3/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6093626 | 0.91 | HRH3 (0.51) | S1PR5PRKAA2DRD2DRD3HRH3 | |
| SCHEMBL2966789 | 0.87 | KCNH2 (0.54) | S1PR5PRKAA2DRD2DRD3HRH3 | |
| SCHEMBL5965774 | 0.83 | PRKAA2 (0.46) | S1PR5PRKAA2DRD2DRD3HRH3 | |
| SCHEMBL6996268 | 0.81 | CACNA1G (0.57) | HRH1 | |
| SCHEMBL6995086 | 0.80 | CCR3 (0.49) | PRKAA2DRD2DRD3HRH2HRH1 | |
| SCHEMBL1730302 | 0.78 | LTA4H (0.63) | DRD2DRD3HRH3HRH2HRH1 | |
| SCHEMBL7030745 | 0.78 | SIGMAR1 (0.56) | HRH3HRH2HRH1 | |
| SCHEMBL6997428 | 0.78 | DRD2 (0.41) | PRKAA2DRD2DRD3HRH2HRH1 | |
| SCHEMBL7035866 | 0.76 | HRH3 (0.49) | HRH3HRH2HRH1 | |
| SCHEMBL6094564 | 0.76 | DRD2 (0.51) | S1PR5DRD2DRD3HRH3HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | US | disclosed |
| EP-1301510-A1 | NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002004446-A1 | NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | KCNH1, LBR, CACNA1E | S1PR5 2701/4885PRKAA2 2937/4885DRD2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.